Actinium Pharmaceuticals Inc
Actinium Pharmaceuticals Inc (ATNM) Covered Calls
Actinium Pharmaceuticals Inc trades in the Biotechnology industry with an IV Rank of 2.98%, low versus the past year. ATNM's highest covered call setup is the $2.50 strike expiring Feb 19, 2027, sorted by theoretical annualized return. It's 67.79% out of the money with 95 days to expiration, a 74.50% return until expiration, and a 286.22% theoretical annualized return. Across the setups shown, annualized returns run from 172.53% to 286.22% at strikes between $2.50 and $2.50, with 95 to 186 days to expiration, as of Nov 16, 2026.
Read more
Running ATNM covered calls helps you generate income from Actinium Pharmaceuticals Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best ATNM covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If ATNM stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling ATNM covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given ATNM covered call is worth writing.
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities.
| 2027-02-19 | 95 | 2.50 | 67.79 | 0.10 | 0.55 | 111.00 | 74.50 | 286.22 | -6.71 | +0.48 | 1,752 | 0.45 |
| 2027-05-21 | 186 | 2.50 | 67.79 | 0.30 | 0.40 | 131.00 | 87.92 | 172.53 | -20.13 | +0.50 | 4,409 | 0.10 |
As of Nov 16, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank2.98% Low
- Market cap (M$)34
- 52 weeks high-37.21%
- 52 weeks low45.95%
- Analyst recommendationStrong Buy
1.00 - Target price$4.50
316.67% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-08-03
- P/E3.22
- Future P/E—
- EPS (ttm)0.34
- EPS growth next 5 years16.05%
As of Nov 18, 2026